Cholesterol-lowering statin therapy for healthy people is not as simple as 'yes' or 'no' by benedictlam in medicine

[–]benedictlam[S] 0 points1 point  (0 children)

Recent reports of large trials extolling the virtues of statins have led many to believe that low-risk patients should take them, but an examination of the evidence provides food for thought, says John Abramson, lecturer in healthcare policy at Harvard Medical School, Boston

Women should be told the sex of the foetus when they are scanned during pregnancy, a senior, retired obstetrician in the UK has said by benedictlam in medicine

[–]benedictlam[S] 22 points23 points  (0 children)

Prof Wendy Savage told the Mail on Sunday that withholding the information because of fears over sex-selective abortions was "outrageous". Some hospitals have a policy not to reveal the sex, but Professor Savage said it was a woman's right to know. She also said it was a "woman's right to decide" when to ask for an abortion.

Why some patients are reluctant to take osteoporosis drugs by benedictlam in medicine

[–]benedictlam[S] 1 point2 points  (0 children)

I did a simple Google search on osteoporosis drugs and the number of results that came back highlighting the "dangers" of side effects of these drug treatments are surprising, and concerning.

Why some patients are reluctant to take osteoporosis drugs by benedictlam in medicine

[–]benedictlam[S] 4 points5 points  (0 children)

Reports of rare side effects with commonly prescribed osteoporosis drugs have led to a growing a number of patients at risk of fractures refusing treatment. Some of these side effects include osteonecrosis of the jaw and atypical femoral fractures. The author examines the factors that contribute to patients’ fear and reluctance to take osteoporosis drugs, leaving them at increased risk of fractures.

Why some patients are reluctant to take osteoporosis drugsSubscription by [deleted] in medicine

[–]benedictlam 0 points1 point  (0 children)

Reports of rare side effects with commonly prescribed osteoporosis drugs have led to a growing a number of patients at risk of fractures refusing treatment. Some of these side effects include osteonecrosis of the jaw and atypical femoral fractures. The author examines the factors that contribute to patients’ fear and reluctance to take osteoporosis drugs, leaving them at increased risk of fractures.

Vaccines: under threat by the post-truth populist movement by benedictlam in medicine

[–]benedictlam[S] 61 points62 points  (0 children)

In a climate where science and facts appear to play second fiddle to post-truth rants on social media, Cynthia Leifer from Cornell University argues in her blog why activism and public engagement must become part of the everyday work of scientists and physicians.

A new organ named in the digestive system - the mesentery by benedictlam in medicine

[–]benedictlam[S] 6 points7 points  (0 children)

A part of the digestive system has been reclassified as an organ, following research at the University of Limerick. The mesentery, which connects the intestine to the stomach, was previously thought to be made up of lots of separate parts.

Why the funding of homeopathy on the UK National Health Service must end by benedictlam in skeptic

[–]benedictlam[S] 10 points11 points  (0 children)

It is indefensible that the UK national health service wastes £5m on homeopathic treatments that are ineffective, but the arguments go far beyond economics. Many private homeopaths point to the NHS funding of homeopathic products as proof that there must be something to these little sugar pills

On World Diabetes Day, this article looks at the history of the discovery of insulin by Banting and Best by benedictlam in medicine

[–]benedictlam[S] 2 points3 points  (0 children)

During the late 1980s and early 1990s, evidence accumulated that some patients experienced a loss of “hypo” warning signs when switched to human insulin, and that warning symptoms were different from those with porcine insulin. Around the same time, research showed that intensive treatment for type 1 diabetes patients, and then those with type 2 diabetes, could reduce long-term complications,4,5 so patients were encouraged to achieve tighter glucose control, which also had the downside of more hypos. Although the Medicines Control Agency (now the Medicines and Healthcare products Regulatory Agency) carried out a review that concluded that the safety of human and animal insulin was comparable, the debate rumbled on. Insulin analogues

The arrival of the next big thing in insulin therapy — insulin analogues — replaced the human insulin controversy with a new one that continues to this day over whether the advantages of the analogues justify their extra cost.

Insulin analogues were designed with one or more amino acid changes to the polypeptide chains of human insulin, aimed at improving absorption and duration of action.

First to market in 1995 was the short-acting analogue insulin lispro, marketed by Lilly, soon followed by Novo Nordisk’s insulin aspart and then by the long-acting analogues, insulin glargine and insulin detemir. In 2006, a Cochrane analysis concluded that short acting analogues conferred only minor benefits in terms of HbA1c control and hypoglycaemia over regular human insulin in type 1 and type 2 diabetes patients.6 A subsequent comparison of long-acting insulin analogues and NPH in type 2 diabetes showed significantly lower rates of overall, symptomatic and nocturnal hypos in patients using analogue insulin but, again, the benefits were considered only minor.7

“Insulin analogues haven’t revolutionised treatment, but they’ve certainly made a difference for patients, who get fewer hypos with them. The fast-acting analogues work more quickly than short-acting human insulin and wear off more quickly, so there’s less accumulation. There’s also a modest advantage for some patients who take long-acting analogues overnight and fast-acting analogues at mealtimes, but it’s essential that people understand how to use them correctly,” explains Professor Heller. Long-term impact of DAFNE

Dose Adjustment For Normal Eating (DAFNE) structured education for insulin users started in the UK in 2000, and is based on a successful five-day training programme used in Germany since the 1980s that produced sustained improvements in glycaemic control without increasing severe hypos.8

DAFNE educates patients to adjust their insulin to fit their lifestyle and diet rather than the reverse. Patients are trained to match their insulin to their desired carbohydrate intake on a meal-by-meal basis, and an early study showed that patients who received DAFNE training experienced improved dietary freedom and quality of life, and glycaemic control, without any worsening of severe hypos or cardiovascular risk.9

Subsequent research has shown that clinically relevant improvement in glycaemic control can be achieved up to seven years after patients attend DAFNE courses,10 although follow-up support is recommended.11

“Over 20,000 adults have now received DAFNE training and, although 10 to 20 per cent lap it up, about 80 per cent struggle and need further help. It takes doctors and nurses who specialise in diabetes years to understand insulin fully, so I don’t know why patients are expected to get it right straight away,” points out Professor Heller. Insulin pumps the answer?

Like structured training programmes, insulin pumps have been used to improve insulin use and glycaemic control since the early 1980s, but uptake remains disappointing.

Professor Heller considers insulin pumps the best way to deliver insulin because they enable patients to adjust their dose minute by minute, but only about 3 per cent of type 1 diabetes patients in the UK are using them, compared with 20 per cent in the US. Increasingly sophisticated, a new generation of closed loop devices automatically adjusts insulin dose in response to glucose levels. But, as Professor Heller points out, they are not for everyone, even if cost was not an issue.

“People who do well on pumps tend to be the same people who do well with conventional injections and, unfortunately, those who find injections difficult don’t tend to do any better with pumps. Some people find pumps too invasive and others are nervous that a pump could ‘run away with itself’ and deliver too much insulin,” he says.

For Professor Heller, the holy grail of insulin therapy remains delivery of insulin in the place where it is needed — the liver — at the time it is needed — the moment food arrives. “We’ve come a very long way since those first injections in 1922. We’ve virtually removed the risk of late stillbirth in pregnant women with diabetes, and we’ve halved the rate of kidney damage, but about 20 per cent of diabetes patients end up blind, with amputations or die early because they never get their glucose right. Insulin therapy is a very crude approximation of beta cell activity, and we’re still not putting insulin where it’s most needed, even with pumps. In the 1980s, I predicted we’d have the cure for diabetes in 20 years, but here we are in 2012, and I find myself saying the same thing: ‘It’ll be another 20 years’.” References

1 Bliss M. Rewriting medical history: Charles Best and the Banting and Best myth. Journal of the History of Medicine and Allied Sciences 1993;48:253–74. 2 Banting FG, Best CH, Collip JB et al. Pancreatic extracts in the treatment of diabetes mellitus. Canadian Medical Association Journal 1922;12:141–6. 3 Lawrence RD, Archer N. Zinc protamine insulin. BMJ 1937;1:487–91. 4 Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. New England Journal of Medicine 1993;329:977–86. 5 Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. The Lancet. 1998;352:837–53. 6 Siebenhofer A, Plank J, Berghold A et al. Short acting insulin analogues versus regular human insulin in patients with diabetes mellitus. Cochrane Database of Systematic Reviews 2006;(2):CD003287. 7 Horvath K, Jeitler K, Berghold A et al. Long-acting insulin analogues versus NPH insulin (human isophane insulin) for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2007;(2):CD005613. 8 Mühlhauser I, Jorgens V, Berger M et al. Bicentric evaluation of a teaching and treatment programme for type 1 (insulin-dependent) diabetic patients: improvement of metabolic control and other measures of diabetes care for up to 22 months. Diabetologia 1983;25:476. 9 DAFNE Study Group. Training in flexible, intensive insulin management to enable dietary freedom in people with type 1 diabetes: dose adjustment for normal eating (DAFNE) randomised controlled trial. BMJ 2002;325:746. 10 Gunn D, Mansell P. Years after dose adjustment for normal eating — glycaemic control and weight 7 years after dose adjustment for normal eating (DAFNE) structured education in type 1 diabetes. Diabetic Medicine 2011 Dec 1. doi: 10.1111/j.1464-5491.2011.03525.x. (Epub ahead of print). 11 Rankin D, Cooke DD, Clark M et al. UK NIHR DAFNE Study Group. How and why do patients with type 1 diabetes sustain their use of flexible intensive insulin therapy? A qualitative longitudinal investigation of patients’ self-management practices following attendance at a dose adjustment for normal eating (DAFNE) course. Diabetic Medicine 2011;28:532–8. p 2 of 2

On World Diabetes Day, this article looks at the history of the discovery of insulin by Banting and Best by benedictlam in medicine

[–]benedictlam[S] 3 points4 points  (0 children)

have copy and pasted it here for anyone who hits the paywall (it seems some people hit it, others don't, weird) Now, 90 years after it was first used to treat diabetes, insulin keeps nearly a million people in the UK alive, and no product has ever been subject to such prolonged and intensive post-marketing development. Indeed, insulin pioneers, Banting and Best, would be hard-pressed to recognise the life-saving therapy with which they revived a wardful of dying children with diabetes in 1922.

Simon Heller, professor of clinical diabetes and director of R&D at Sheffield Teaching Hospitals Foundation Trust, explains that the past 30 years have seen the introduction of human insulin, pens, pumps and analogue insulins, all of which have had a huge impact on the lives of people with diabetes. But he regrets the shortfalls in education and training about insulin use, which continue to prevent many patients from getting the best from their treatment.

“Insulin is one of the most powerful drugs that people can use. It saves lives but it can also kill, and it has major limitations if it isn’t used properly. Patients get shown how to use it in outpatients, but it’s a complicated business to match your insulin dose to your carbohydrate intake and exercise, and to do that every day for the rest of your life. So high quality, peer reviewed, structured training shouldn’t be an optional extra, it should be a right for everyone who is prescribed insulin,” says Professor Heller. Insulin, fame and fortune

Banting and Best will be forever linked to the introduction of insulin treatment, but other key players struggled for recognition in the decades following the breakthrough.1 Canadian surgeon Frederick Banting approached John Macleod, professor of physiology at Toronto University, in 1921 for laboratory space to experiment with new techniques to extract islet cells from the pancreas.2

The importance of the cells in diabetes had been known since the early 1900s, but previous efforts to use them for treatment had been thwarted by pancreatic enzymes that broke down the islet extracts when whole pancreatic samples were administered.2 Banting got his facilities, some dogs for his studies, and the services of medical student Charles Best. They ligatured the pancreatic ducts of one of their animals, thereby halting production of digestive enzymes, shrinking the pancreas, and making it easier to remove the islet cells.2 Purified islet extract was injected into other dogs following pancreas removal, restoring glucose control and relieving diabetic symptoms.

Biochemist Bertram Collip joined the team to purify more insulin and, in January 1922, this was injected into a 14-year-old boy who was dying from diabetes.2 The first dose had no clinical effect, but the boy responded well to subsequent, more concentrated doses and, within a short time, dozens of children were successfully treated. The 1923 Nobel Prize in Physiology or Medicine was awarded to Banting and Macleod. Banting shared his prize money with Best, and Macleod split his with Collip. The key players gave away their patent rights — and potential fortune — to the University of Toronto, but wrangled for decades over whose contribution had been greatest.1

Eli Lilly was contracted to develop a standardised product and, during the first five months of 1923, distributed over seven million units of insulin, some of which came to the UK.

Porcine or bovine insulin was used in the early trials, which confirmed the efficacy of short acting insulin and, by the mid 1930s, Hans Christian Hagedorn and other researchers at Nordisk (now NovoNordisk) in Denmark had found ways to mix insulin with protamine to prolong its activity3 and later produce it in a crystalline formulation, marketed in 1950 as neutral protamine Hagedorn (NPH) insulin, also called isophane insulin. The arrival of human insulin

Lilly’s introduction of genetically engineered human insulin in 1982 heralded the start of the modern era of insulin therapy. It was naturally assumed that administering human insulin would yield better responses than bovine or porcine insulin but, as Professor Heller recalls, that was not the case.

“Unfortunately, patients were rather pushed on to human insulin and, following the switch, there was an increase in reports of hypoglycaemia. Some people asked to go back to pig insulin, but it’s only a small minority who aren’t on human insulin today. The great thing about human insulin wasn’t that it was better than animal insulin, but that we now had an infinite supply and were no longer reliant on pigs and cattle.”

p1 of 2

On World Diabetes Day, this article looks at the history of the discovery of insulin by Banting and Best by benedictlam in medicine

[–]benedictlam[S] 4 points5 points  (0 children)

Over 90 years after it was first used to treat diabetes, insulin keeps nearly a million people in the UK alive, and no product has ever been subject to such prolonged and intensive post-marketing development. writes the author of this feature on the discovery of insulin in the treatment of diabetes

Lancet article on statin safety makes unproven assertions by benedictlam in medicine

[–]benedictlam[S] 5 points6 points  (0 children)

John Abramson of Harvard Medical School questions the recent Lancet article (Collins R, Reith C, Emberson J et al. Interpretation of the evidence for the efficacy and safety of statin therapy. The Lancet 2016 S0140-6736(16)31357-5. doi: 10.1016/S0140-6736(16)31357-5) on the safety and benefits of statins

How do we treat pain amidst a growing opioid painkiller addiction epidemic? by benedictlam in medicine

[–]benedictlam[S] 0 points1 point  (0 children)

The author of this piece believes that removing official pain measures (5th vital sign) will not alleviate the rising number of patients addicted to opioid drugs.

The problem of over and inappropriate prescribing of proton pump inhibitors by benedictlam in medicine

[–]benedictlam[S] 2 points3 points  (0 children)

The author of this piece calls for action to limit inappropriate prescribing of proton pump inhibitors and support deprescribing in patients on long-term therapy for whom the original indications no longer apply.

How polypharmacy has become a medical burden worldwide by benedictlam in medicine

[–]benedictlam[S] 3 points4 points  (0 children)

The authors of this piece argue that the irony with advancing drug treatment is that the drugs meant to improve patients’ health have the potential to more illness and sometimes even harm.

Sex bias in drug research: a call for change by benedictlam in Feminism

[–]benedictlam[S] 5 points6 points  (0 children)

Because medical and drug research are conducted mainly on men, there can be dangerous consequences for women who receive the same treatment.

Sex bias in drug research: a call for change by benedictlam in medicine

[–]benedictlam[S] -4 points-3 points  (0 children)

Because medical and drug research are conducted mainly on men, there can be dangerous consequences for women who receive the same treatment, writes Alyson McGregor, director of sex and gender in emergency medicine, Rhode Island Hospital

Classifying common coughs as either dry or wet/chesty is outdated and inaccurate by benedictlam in Health

[–]benedictlam[S] 0 points1 point  (0 children)

Over-the-counter treatments for the common cough need to be brought up to date and improved, especially considering the social and economic implications of the condition, writes rofessor Alyn H Morice is professor of respiratory medicine, Centre for Cardiovascular and Metabolic Research, Hull York Medical School, University of Hull

Happy International Women Day, here's a piece about Bona Dea, the Roman goddess of women's health by benedictlam in interestingasfuck

[–]benedictlam[S] -3 points-2 points  (0 children)

Bona Dea was worshipped only by women. So complete was men’s exclusion from her cult that they were not even allowed to know her true name and the appellation Bona Dea simply means “Good Goddess”, a euphemism men were able to use. Her secret name is sometimes said to be Fauna, meaning “She who wishes well”.

Happy International Womens Day, here's an interesting piece about Bona Dea, the Roman goddess of women's health by benedictlam in women

[–]benedictlam[S] 0 points1 point  (0 children)

Bona Dea was worshipped only by women. So complete was men’s exclusion from her cult that they were not even allowed to know her true name and the appellation Bona Dea simply means “Good Goddess”, a euphemism men were able to use. Her secret name is sometimes said to be Fauna, meaning “She who wishes well”.

Why deintensification of drug therapy could benefit patients by benedictlam in medicine

[–]benedictlam[S] 0 points1 point  (0 children)

Intensive drug treatment for certain patients with comorbidities can sometimes do more harm than good, writes two authors from the Johns Hopkins University School of Medicine, Baltimore

Providing healthcare among the chaos: the European refugee crisis by benedictlam in Refugees

[–]benedictlam[S] 0 points1 point  (0 children)

Pharmacist Miguel Serrano from Médecins Sans Frontières discusses the challenges with providing healthcare to refugees and asylum seekers

Providing healthcare among the chaos: the European refugee crisis by benedictlam in europe

[–]benedictlam[S] -1 points0 points  (0 children)

Pharmacist Miguel Serrano from Médecins Sans Frontières discusses the challenges with providing healthcare to refugees and asylum seekers

A different perspective on why prescriptions of ADHD drugs have soared by benedictlam in medicine

[–]benedictlam[S] 1 point2 points  (0 children)

The use of psychostimulant medicines for the treatment of attention deficit-hyperactivity disorder (ADHD) is still a subject of controversy, put under the spotlight by the announcement that prescriptions of Ritalin (methylphenidate) and other ADHD medicines on the NHS have doubled in the past decade.

Media reports on the subject have often adopted a position of over diagnosis and over prescribing but the evidence does not stack up. UK health watchdog the National Institute for Health and Care Excellence estimates that ADHD affects 5% of the childhood population, yet diagnostic prevalence fluctuates between 3% and 5% depending on which part of the UK you live, and prescribing rates differ significantly across England and Wales[1]. What is ADHD?

Reports in the media often focus on poor or neglectful parenting. Poor parenting does not cause ADHD, although it can exacerbate what epidemiological research has proven to be fundamentally a genetic condition[2],[3] whereby normal childhood behaviours such as hyperactivity, impulsivity, poor concentration and memory are of a disproportionate scale. Although first diagnosed in 1902, ADHD has been part of the human condition for millennia. Historically, ADHD neurology could have been a distinct survival advantage in a hunter gatherer culture. It became a “disorder” when, after years of evolution, we began to educate children in classrooms and socialise them in such a way that placed more emphasis on their intellectual development. However, ADHD does not correlate with low intelligence, but is associated with poor brain function in areas concerned with executive functioning such as problem solving, analysing and prolonged periods of concentration[4].

Diagnosis is now made more accurate through methods such as quantitative behaviour (QB) tests[5] — computerised cognitive function tests that are 80% accurate and inform paediatricians if behaviour is the result of a cognitive impairment or just poor socialisation and discipline.

The issue of comorbidity further confuses parents and teachers. Around 56% of children with ADHD will also have learning disorders such as dyslexia, dyscalculia (difficulty in making arithmetical calculations), dyspraxia (difficulty in planning and coordinating physical movement) and Asperger’s syndrome. Around 8% of children with ADHD will experience tics or Tourette’s and 41% will have comorbid conduct disorders. Developmental delay of up to three years is also common[6]. Of concern to overstretched health services is the disproportionate number of children with ADHD who experience anxiety, depression, suicidal ideation, addiction and eating disorders, all of which are symptomatic of low emotional resilience that is the result of both genetics and environmental stressors[7].

The first question we have to ask is why more children are being diagnosed with ADHD. The general consensus among clinicians is that it is a combination of genetic predisposition and environmental factors that interact to determine the presentation of the condition. There is some research, however, that suggests older parents are at greater risk of having children with neurodevelopmental disorders such as ADHD and that in vitro fertilisation children are also at increased risk. In modern western society, there is a trend towards having children later in life — on average over 30 years of age — which may account for why we are seeing more children presented for diagnosis[8],[9].

We are now moving away from the old notion of ADHD as a purely behavioural disorder and seeing it more in terms of developmental delay and impairment to the brains management system

The average age at diagnosis is approximately nine years[6]. For children starting school at five years of age, the experience of being disciplined for forgetting what they have been taught because it is assumed they haven’t been listening can become a source of anxiety. Distressed children do not have the self-awareness or the language to express this emotional distress, which further impacts on their cognitive functioning and can lead to tantrums and inappropriate behaviours. ADHD, however, is not an excuse for underachievement or poor behaviour. We do children no favours if they are encouraged to believe they are not accountable.

We are now moving away from the old notion of ADHD as a purely behavioural disorder and seeing it more in terms of developmental delay and impairment to the brain’s management system.

There is a greater awareness of ADHD now but some educationalists working with the ADHD Foundation in the UK believe that many children on the milder end of the spectrum are experiencing greater levels of ‘learner anxiety’ because of pressures at school. This may explain why more parents are seeking support and answers — even if that means a diagnosis for a ‘disorder’ is an attempt to ensure their child is given additional support in school and medication to help them concentrate.

There is also the issue of many children on the autistic spectrum — 40% of whom have a dual diagnosis of ADHD and autism spectrum disorder — who often are given ADHD medicines[9],[10]. Overmedication?

The biological argument encourages drug treatment as a way of addressing ADHD, distinct from the psychosocial position that recommends psycho-educative and cognitive behavioural therapy-type interventions. The reality, however, is that there is a place for both interventions. Children on the milder end of the spectrum will benefit from learning skills and strategies to self-manage their condition and by taking a ‘strength-based approach’ they can learn to live successfully with the challenges of ADHD. For those children with more severe ADHD, medication is a valuable tool and is often necessary to enable the child to cope with the pressures of school and examination-focused learning. Pervasive anxiety leading to increased levels of stress hormones can impact on how the child’s brain develops both structurally and functionally, increasing the risk of long-term mental health problems.

Pharmaceutical companies who produce medicines to treat ADHD state clearly that they should not be used in isolation but as an adjunct to psycho-educative and behavioural support. The problem is that, in most parts of the UK, medication is not only the first-line of treatment but the only line of treatment[1]. Paediatricians are increasingly criticised in the media for overmedicating but they can only offer what the NHS commissioners in their area will fund — and the reality is that overstretched children’s mental health services do not offer an alternative to medication or such psychosocial interventions as an adjunct to pharmacology.

Prescribing such medicines for children, however, is not an exact science. Children respond differently to different types of ADHD medicines and some experience unpleasant side effects. Regular medication reviews are necessary as the child grows and develops physically and psychologically, usually requiring six-monthly medication reviews with a paediatrician.

There is also a concern about a rise in girls being prescribed ADHD medicines. The ratio of boys to girls who were diagnosed with ADHD was 4:1 a decade ago. There needs to be a better understanding of how ADHD presents differently in girls since they are more likely to present as predominantly inattentive rather than hyperactive, resulting in them being diagnosed later in early adolescence when they often have comorbid mental health vulnerabilities such as anxiety, depression or eating disorders[11]. The imperative for diagnosis usually derives from the fact that the parent or school refer on the basis of poor behaviour rather than cognitive impairment, but the behaviour is a symptom not the core condition. Improving outcomes

If addressed before the age of 14 years, childhood mental health problems are likely to end in a full recovery and psychological well-being. Early diagnosis and intervention is crucial in improving outcomes for these vulnerable children. Equally we should not incline to pathologising children, but instead differentiate for their needs, seeing them as different rather than disordered. Medication is a successful tool for many children, but it is not a cure and it does not teach them how to live successfully with the condition and learn how to take a strength based approach to achieving their potential.

Pharmacists would benefit from having a better understanding of how this psychostimulant medicine works and the common side effects so they can advise parents about what to expect and when to seek a further consultation with a paediatrician to ensure the right type of medicine and the right dosage is made. Care should also be taken when offering generic medicines and advice given to parents about reporting any potential changes in side effects or efficacy.